💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…
User | Tweets |
---|---|
@nodramahere7 | 3 |
@otcdynamics | 3 |
@stock_titan | 2 |
@newsfilterio | 2 |
@SmallCapsDaily | 2 |
![]() |
@ExecPayOrg Adamas Pharmaceuticals CEO Neil McFarlane's 2020 pay slips 19% to $1.7M https://t.co/ObFbbRCBb6 $ADMS #execpay April 19th 2021, 8:04pm |
![]() |
@StockTexts $ADMS Adamas Pharmaceuticals, Inc. SEC Filing: Form DEFA14A https://t.co/T4KTkslXzc April 19th 2021, 8:04pm |
![]() |
@fintel_io $ADMS / Adamas Pharmaceuticals files form DEF 14A https://t.co/52VYsX5bEq April 19th 2021, 8:04pm |
![]() |
@SwingTradeBot Rose Above 50 DMA today: $ADMS ... https://t.co/qwiJH6dPDe April 19th 2021, 5:04pm |
![]() |
@TripsG11 $ADMS moving up nicely today - above resistance and that top channel line Like for more! #uncleeagleindicator… https://t.co/uGg337sLG6 April 19th 2021, 5:04pm |
![]() |
@SmallCapsDaily $ADMS Survey data detailing impact of OFF time and dyskinesia in people affected by Parkinsons disease presented at… https://t.co/5Ez4X3yQUn April 19th 2021, 2:04pm |
![]() |
@otcdynamics $ADMS Survey data detailing impact of OFF time and dyskinesia in people affected by Parkinson’s disease presented a… https://t.co/xhZcXiwdks April 19th 2021, 1:04pm |
![]() |
@stock_titan $ADMS Survey data detailing impact of OFF time and dyskinesia in people affected by Parkinson’s disease presented a… https://t.co/hk4XSWlDQO April 19th 2021, 1:04pm |
![]() |
@Risk75742306 Is this a beautiful chart or WHAT!!? ? $ADMS https://t.co/5DSPoSWepz April 17th 2021, 1:04pm |
![]() |
@SwingTradeBot Recent $ADMS technical alerts: 20 DMA Support plus 7 more alerts... https://t.co/6STYExEpKx April 17th 2021, 1:04pm |
![]() |
@newsfilterio Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting $ADMS https://t.co/noQ0iFRyxt April 16th 2021, 5:04am |
![]() |
@nodramahere7 RT @otcdynamics: $ADMS Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting https://t.co/cV1N5SkLfS April 15th 2021, 6:04pm |
![]() |
@nodramahere7 RT @SmallCapsDaily: $ADMS Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting Business Wire https:… April 15th 2021, 6:04pm |
![]() |
@tmustang804 $ADMS low volume, taking lotto at 5.17 previous high break #potentialaddalert #addalert April 15th 2021, 6:04pm |
![]() |
@SmallCapsDaily $ADMS Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting Business Wire… https://t.co/iDolcxjW6A April 15th 2021, 2:04pm |
![]() |
@otcdynamics $ADMS Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting https://t.co/cV1N5SkLfS April 15th 2021, 1:04pm |
![]() |
@nodramahere7 RT @SeekingAlpha: $ADMS - Circling Back On Adamas Pharmaceuticals. https://t.co/QKGbo2hBc4 #stocks #trading #investing April 14th 2021, 8:04pm |
![]() |
@AnthonyPatafio $adms good price action past 2 days! Wonder if they said anything good at conference today. #stocks #smallcapstocks April 14th 2021, 8:04pm |
![]() |
@npsullia $ADMS Starting in a while https://t.co/vZeJYTu1zc April 14th 2021, 6:04pm |
![]() |
@SeekingAlpha $ADMS - Circling Back On Adamas Pharmaceuticals. https://t.co/QKGbo2hBc4 #stocks #trading #investing April 14th 2021, 4:04pm |
![]() |
@tradingfitgirl $ADMS Adamas Pharmaceuticals Shares See Volume; Co Granted U.S. Patent Titled 'Methods and compositions for the tre… https://t.co/NvHUIDUM5g April 13th 2021, 2:04pm |
![]() |
@otcdynamics $ADMS Adamas to Present at Upcoming Needham Conference https://t.co/kdZ3T4FPCR April 7th 2021, 9:04pm |
![]() |
@newsfilterio Adamas to Present at Upcoming Needham Conference $ADMS https://t.co/Unxdje9hx0 April 7th 2021, 9:04pm |
![]() |
@stock_titan $ADMS Adamas to Present at Upcoming Needham Conference https://t.co/VQEfNNEcvl April 7th 2021, 9:04pm |
![]() |
@TraderTexMmex RT @TraderTexMex: $ADMS offering April 5th 2021, 7:04am |
![]() |
@WALLSTREETODDS_ $ADMS Out of the 138 other times ADMS was up 7.3% during a trading day, 59% of the time it traded lower by the nex… https://t.co/zmglsClY0h April 5th 2021, 6:04am |
![]() |
@fm23 $ADMS https://t.co/jOGmdBqL8B April 1st 2021, 3:04pm |
![]() |
@nodramahere7 RT @newsfilterio: Adamas announces new peer-reviewed data to support Gocovri benefit in Parkinson’s $ADMS https://t.co/jTLYl37FBg March 29th 2021, 7:03pm |
![]() |
@nodramahere7 RT @newsfilterio: Adamas' Gocovri Treatment Doubles ON Time Without Dyskinesia In Parkinson's disease, New Analysis Shows $ADMS https://t.c… March 29th 2021, 7:03pm |
![]() |
@newsfilterio Adamas' Gocovri Treatment Doubles ON Time Without Dyskinesia In Parkinson's disease, New Analysis Shows $ADMS https://t.co/TqHFGewm19 March 29th 2021, 7:03pm |
![]() |
@newsfilterio Adamas announces new peer-reviewed data to support Gocovri benefit in Parkinson’s $ADMS https://t.co/jTLYl37FBg March 29th 2021, 6:03pm |
![]() |
@Briefingcom $ADMS: Adamas Pharmaceuticals publishes data demonstrating GOCOVRI more than doubled ON time without dyskinesia in.… https://t.co/sK4kfq0lH1 March 29th 2021, 3:03pm |
![]() |
@SmallCapsDaily $ADMS Adamas publishes new data analyses demonstrating GOCOVRI treatment more than doubled ON time without dyskines… https://t.co/u95WqoOAje March 29th 2021, 2:03pm |
![]() |
@BioMedReports $ADMS Adamas Pharmaceuticals announced the publication of an article entitled "Amantadine ER significantly increase… https://t.co/cH09rOKXPv March 29th 2021, 2:03pm |
![]() |
@StckPro $ADMS NEW ARTICLE : Adamas publishes new data analyses demonstrating GOCOVRI treatment more than doubled ON time wi… https://t.co/aFFm7tgMeH March 29th 2021, 2:03pm |
![]() |
@SwingTradeBot Recent $ADMS technical alerts: Bollinger Band Squeeze plus 6 more alerts... https://t.co/6STYExmOSZ March 29th 2021, 1:03pm |
![]() |
@OpenOutcrier $ADMS (+4.5% pre) Adamas Pharma (ADMS) publishes new data analyses demonstrating GOCOVRI treatment more than double… https://t.co/qNdbsG4zmP March 29th 2021, 1:03pm |
![]() |
@Beeken_health $ADMS - Adamas publishes new data analyses demonstrating GOCOVRI treatment more than doubled ON time without dyskin… https://t.co/drT8iqBwNL March 29th 2021, 1:03pm |
![]() |
@2ndwavve $adms 143 % short growth. Squeeeze me March 29th 2021, 1:03pm |
![]() |
@FlashAlert_me $ADMS [15s. delayed]: Issued Press Release on March 29, 09:15:00: Adamas publishes new data analyses demonstrating… https://t.co/lduuLbsEWo March 29th 2021, 1:03pm |
![]() |
@fm23 $ADMS https://t.co/7G6F1VFkyf March 29th 2021, 1:03pm |
![]() |
@sbwcws Adamas publishes Gocovri data on patients with Parkinson's disease $ADMS March 29th 2021, 1:03pm |
![]() |
@StarvinMargin 0918 $ADMS parkinsons related https://t.co/sEJ60OeHCq March 29th 2021, 1:03pm |
![]() |
@FearLessTraDeRx $ADMS publishes new data analyses demonstrating GOCOVRI treatment more than doubled ON time without dyskinesia i… https://t.co/Fw7MFxueHI March 29th 2021, 1:03pm |
![]() |
@2ndwavve $ADMS Adamas publishes new data analyses demonstrating GOCOVRI treatment more than doubled ON time without dyskines… https://t.co/BQjeMQpgie March 29th 2021, 1:03pm |
![]() |
@tradingfitgirl $ADMS Adamas publishes new data analyses demonstrating GOCOVRI treatment more than doubled ON time without dyskines… https://t.co/0mtk3zV0Vv March 29th 2021, 1:03pm |
![]() |
@IamCountSPACula $ADMS Adamas publishes new data analyses demonstrating GOCOVRI treatment more than doubled ON time without dyskines… https://t.co/rHLQ0867AT March 29th 2021, 1:03pm |
![]() |
@James__BondOO7 RT @stock_titan: $ADMS Adamas publishes new data analyses demonstrating GOCOVRI treatment more than doubled ON time without dyskinesia in p… March 29th 2021, 1:03pm |
![]() |
@StarlordTt $ADMS Adamas publishes new data analyses demonstrating GOCOVRI treatment more than doubled ON time without dyskines… https://t.co/EFIvHDoeFw March 29th 2021, 1:03pm |
![]() |
@stock_titan $ADMS Adamas publishes new data analyses demonstrating GOCOVRI treatment more than doubled ON time without dyskines… https://t.co/7tSqwVY83a March 29th 2021, 1:03pm |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2021. All rights reserved.